Historical Valuation
Travere Therapeutics Inc (TVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 5.90 is considered Fairly compared with the five-year average of 38.50. The fair price of Travere Therapeutics Inc (TVTX) is between 24.95 to 43.95 according to relative valuation methord.
Relative Value
Fair Zone
24.95-43.95
Current Price：35.60
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Travere Therapeutics Inc (TVTX) has a current Price-to-Book (P/B) ratio of 48.06. Compared to its 3-year average P/B ratio of 17.38 , the current P/B ratio is approximately 176.57% higher. Relative to its 5-year average P/B ratio of 13.25, the current P/B ratio is about 262.76% higher. Travere Therapeutics Inc (TVTX) has a Forward Free Cash Flow (FCF) yield of approximately -1.67%. Compared to its 3-year average FCF yield of -25.43%, the current FCF yield is approximately -93.45% lower. Relative to its 5-year average FCF yield of -16.77% , the current FCF yield is about -90.06% lower.
P/B
Median3y
17.38
Median5y
13.25
FCF Yield
Median3y
-25.43
Median5y
-16.77
Competitors Valuation Multiple
AI Analysis for TVTX
The average P/S ratio for TVTX competitors is 6.37, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX.O) exhibits a P/S ratio of 5.90, which is -7.3% above the industry average. Given its robust revenue growth of 162.11%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TVTX
1Y
3Y
5Y
Market capitalization of TVTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TVTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TVTX currently overvalued or undervalued?
Travere Therapeutics Inc (TVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 5.90 is considered Fairly compared with the five-year average of 38.50. The fair price of Travere Therapeutics Inc (TVTX) is between 24.95 to 43.95 according to relative valuation methord.
What is Travere Therapeutics Inc (TVTX) fair value?
TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Travere Therapeutics Inc (TVTX) is between 24.95 to 43.95 according to relative valuation methord.
How does TVTX's valuation metrics compare to the industry average?
The average P/S ratio for TVTX's competitors is 6.37, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of 5.90, which is -7.30% above the industry average. Given its robust revenue growth of 162.11%, this premium appears sustainable.
What is the current P/B ratio for Travere Therapeutics Inc (TVTX) as of Jan 10 2026?
As of Jan 10 2026, Travere Therapeutics Inc (TVTX) has a P/B ratio of 48.06. This indicates that the market values TVTX at 48.06 times its book value.
What is the current FCF Yield for Travere Therapeutics Inc (TVTX) as of Jan 10 2026?
As of Jan 10 2026, Travere Therapeutics Inc (TVTX) has a FCF Yield of -1.67%. This means that for every dollar of Travere Therapeutics Inc’s market capitalization, the company generates -1.67 cents in free cash flow.
What is the current Forward P/E ratio for Travere Therapeutics Inc (TVTX) as of Jan 10 2026?
As of Jan 10 2026, Travere Therapeutics Inc (TVTX) has a Forward P/E ratio of 39.39. This means the market is willing to pay $39.39 for every dollar of Travere Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Travere Therapeutics Inc (TVTX) as of Jan 10 2026?
As of Jan 10 2026, Travere Therapeutics Inc (TVTX) has a Forward P/S ratio of 5.90. This means the market is valuing TVTX at $5.90 for every dollar of expected revenue over the next 12 months.